Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOPE: Induction Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma
NCT07711470Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2026; status: active, not recruiting.
02
Drugs
sugemalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07711470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711470.